New Glenn pad explosion fallout & Webb spots black-hole-first galaxy - Tech News (May 29, 2026)

[0:36] New Glenn pad explosion fallout

In space news first, Blue Origin’s New Glenn rocket exploded during a static-fire test Thursday evening at its Florida launch site. The failure happened shortly after ignition, and early indications point to the first-stage engine section, which is powered by seven BE-4 engines. The good news is simple: no injuries, and no payload was on board—Amazon’s Kuiper satellites were reportedly stored safely nearby. The bad news is harder to wave away. Early accounts suggest serious damage to launch pad infrastructure, the kind that doesn’t get fixed in a weekend. If repairs drag on for months, New Glenn’s flight cadence—and even its near-term availability—could slip beyond 2026. That matters because New Glenn isn’t just a commercial launcher; it’s woven into NASA’s Artemis-era logistics, including newly awarded plans to deliver lunar rovers in 2028. And Blue Origin’s own Blue Moon lander ambitions, especially the human-rated concepts, look a lot more stressful when your heavy-lift rocket is suddenly offline.

On the drug development side, the Chan Zuckerberg-backed Biohub has unveiled an AI “world model” for protein biology, based on a new generation of evolutionary-scale modeling. The pitch is straightforward: proteins are at the heart of many medicines, but designing them is slow and expensive. If an AI model can better predict how proteins behave and how small changes affect stability or function, it can speed up the search for therapies. Biohub says it has already validated some predictions in lab work, including protein binders for cancer and immune targets that reactivated immune cells in tests. The plan to release models as open-source is also notable, because it pushes the field toward shared infrastructure rather than purely proprietary advantage—though real progress will still hinge on experimental validation and clinical outcomes.

In cardiology, early Phase 1b results for VERVE-102 suggest a one-time gene therapy could dramatically lower LDL cholesterol for high-risk patients. The top dose reported an average LDL reduction around 62% after a single infusion, by switching off the PCSK9 gene in the liver. It’s still early-stage, and long-term safety and durability are the whole game here. But the significance is clear: if later trials confirm the effect, this is a shift from lifelong medication adherence toward a “done once” intervention—potentially a very different future for patients who struggle to keep LDL under control.

And one more medical device worth flagging: a Stanford-led team, working with Oxford and UC San Diego, reported a proof-of-concept wearable ultrasound patch designed to monitor a fetus for hours, rather than relying on occasional snapshots. In a study with pregnant participants, the patch’s measurements closely matched conventional ultrasound. The potential win is reducing false alarms and catching meaningful changes earlier—especially in conditions where fetal blood flow can vary in ways that don’t always mean immediate danger, but still warrant closer attention. The current system still has practical constraints, but it’s a step toward more continuous, accessible prenatal monitoring.

Now to quantum computing, where the politics are getting as interesting as the physics. The U.S. Commerce Department signed letters of intent to deploy about two billion dollars across nine quantum computing and hardware firms under the CHIPS and Science Act. The market reaction wasn’t just about the money—it was about the structure: the government plans to take minority equity stakes rather than operating purely through conventional grants. Supporters see that as a way to add stability and accelerate domestic capacity in a strategically important field. Critics see a risky precedent: government as shareholder, implicitly picking winners in a speculative industry. Either way, it’s a notable change in how Washington may bankroll frontier tech—and how investors may price in an explicit policy backstop.

IBM, for its part, says it plans to spend more than ten billion dollars over the next five years to pursue a large-scale, fault-tolerant quantum computer by 2029. It’s a massive commitment in a domain where “promising” has often meant “not yet practical.” The combination of government support and deep-pocketed incumbents suggests quantum is moving from science project territory into an industrial race—still uncertain, but increasingly well-funded.

On the streets, Waymo is starting to offer select public riders trips in its new “Ojai” robotaxi—positioned as cheaper to build and more capable in tougher weather than earlier models. The pilot begins with some riders in San Francisco, Los Angeles, and Phoenix, with broader rollout planned in additional U.S. cities later this summer. Waymo’s bigger story is scale: it’s aiming for thousands of these vehicles by the end of 2026. That expansion push comes while the company also manages the less glamorous side of autonomy—recalls, edge cases like flooded roads, and operational pauses when environments get unpredictable. The lesson remains: the tech is advancing, but the rollout is still a careful choreography between capability, cost, and public safety.

Finally, a quick note on software supply chains and workforces—two places where “AI era” pressures show up in very different ways. Developer Andrew Nesbitt published a “package manager matrix” mapping which package managers can install other package managers. It’s a quirky idea with a serious implication: the same vulnerable upstream component can be repackaged and redistributed through many paths, making security tracking harder than it looks. As software stacks get more layered, visibility into those layers becomes a real operational need, not just trivia. And in China, JD.com founder Liu Qiangdong said he’ll try to ensure the company’s large workforce doesn’t lose jobs as JD expands AI and robotics. He framed it as retraining and redeployment rather than layoffs, with training bases aimed at roles like maintaining automated systems. It’s also a reminder that the adoption of automation isn’t only a technical story—it’s a social contract question, and different countries are actively shaping the rules around it.